Bengaluru-based MedGenome, a leader in genomic diagnostics and research, has launched India’s first CNS Tumour Methylation Classifier Test. The test can classify and differentiate more than 90 types of brain and central nervous system (CNS) tumours, enabling doctors to make highly accurate and personalised treatment decisions.
The test was introduced at a precision oncology symposium in Mumbai, jointly hosted by MedGenome and Illumina, the global leader in DNA sequencing. Nearly 200 oncologists, neuro-oncology surgeons, pathologists, and researchers attended the event.
Brain and CNS tumours are among the most complex cancers to diagnose. While histology remains the standard approach, MedGenome’s test adds deeper molecular insights. By using DNA methylation profiling, it maps chemical modifications across the genome to generate a tumour-specific profile.
This profile is then matched against a global reference database, allowing accurate identification of even rare or hard-to-classify tumour types. The results support precise diagnosis, guide treatment response predictions, and enable tailored therapeutic strategies.
The CNS Tumour Methylation Classifier Test is aligned with the World Health Organization’s 2021 guidelines for CNS tumour classification. Results are delivered within 21 days, and the report includes WHO grade assignment, genome-wide copy number profiling, and detection of key gene alterations—matching international best practices.